Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRUCE: zodasiran in adolescents with homozygous familial hypercholesterolemia
2025-523662-24-00Phase 3Authorised
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of zodasiran in homozygous familial hypercholesterolemia (HoFH), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent change from baseline to Month 12 in fasting LDL-C. Planned start Sep 2026; status: authorised.
02
Drugs
zodasiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2025-523662-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523662-24-00.